299 References Recommended by Dr. Robert Melamine

 

PART ONECannabinoids and the Circulatory System 12/19/2016
1. Kreuter, M. et al. [Cannabis–Position Paper of the German Respiratory Society (DGP)]. Pneumologie 70, 87-97 (2016).
2. Nędza, J. et al. [Cannabinoid and cathinone designer drugs – the workings and selected methods of analysis]. Pol Merkur Lekarski 41, 56-59 (2016).
3. Khan, M. I. et al. The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. Curr Pharm Des 22, 1756-1766 (2016).
4. Von Der Haar, J. et al. Synthetic Cannabinoids and Their Effects on the Cardiovascular System. J Emerg Med 50, 258-262 (2016).
5. Gruden, G., Barutta, F., Kunos, G. & Pacher, P. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol 173, 1116-1127 (2016).
6. Le Boisselier, R., Alexandre, J., Lelong-Boulouard, V. & Debruyne, D. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther (2016).
7. Schlabritz-Loutsevitch, N., German, N., Ventolini, G., Larumbe, E. & Samson, J. Fetal Syndrome of Endocannabinoid Deficiency (FSECD) In Maternal Obesity. Med Hypotheses 96, 35-38 (2016).
8. Benyó, Z., Ruisanchez, É., Leszl-Ishiguro, M., Sándor, P. & Pacher, P. Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol 310, H785-801 (2016).
9. Kaur, R., Ambwani, S. R. & Singh, S. Endocannabinoid System: A Multi-Facet Therapeutic Target. Curr Clin Pharmacol 11, 110-117 (2016).
10. Hsin-Hung Chen, M. et al. Detection and Characterization of the Effect of AB- FUBINACA and Its Metabolites in a Rat Model. J Cell Biochem 117, 1033-1043 (2016).
11. Zakrzeska, A., Grędziński, T., Kisiel, W. & Chabielska, E. Cannabinoids and haemostasis. Postepy Hig Med Dosw (Online) 70, 760-774 (2016).
12. Hind, W. H., England, T. J. & O’Sullivan, S. E. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. Br J Pharmacol 173, 815-825 (2016).
13. Hermanns-Clausen, M. et al. Adverse effects after the use of JWH-210 – a case series from the EU Spice II plus project. Drug Test Anal 8, 1030-1038 (2016).
14. Marichal-Cancino, B. A., Fajardo-Valdéz, A., Ruiz-Contreras, A. E., Méndez-Díaz, M. & Prospéro-García, O. Advances in the Physiology of GPR55 in the Central Nervous System. Curr Neuropharmacol (2016).
15. Riederer, A. M. et al. Acute Poisonings from Synthetic Cannabinoids – 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep 65, 692-695 (2016).
16. Altınok, A. et al. Δ9-tetrahydrocannabinol treatment improved endothelium- dependent relaxation on streptozotocin/nicotinamide-induced diabetic rat aorta. Acta Physiol Hung 102, 51-59 (2015).
17. Shore, D. M. & Reggio, P. H. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharmacol 6, 69 (2015).
18. Moris, D., Georgopoulos, S., Felekouras, E., Patsouris, E. & Theocharis, S. The
effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe.
Expert Opin Ther Targets 19, 1261-1275 (2015).
19. Su, E. N., Kelly, M. E., Cringle, S. J. & Yu, D. Y. Role of Endothelium in
Abnormal Cannabidiol-Induced Vasoactivity in Retinal Arterioles. Invest
Ophthalmol Vis Sci 56, 4029-4037 (2015).
20. Karagiannakis, D. S., Papatheodoridis, G. & Vlachogiannakos, J. Recent advances
in cirrhotic cardiomyopathy. Dig Dis Sci 60, 1141-1151 (2015).
21. Romero-Sandoval, E. A., Asbill, S., Paige, C. A. & Byrd-Glover, K. Peripherally
Restricted Cannabinoids for the Treatment of Pain. Pharmacotherapy 35, 917-925
(2015).
22. Clark, B. C., Georgekutty, J. & Berul, C. I. Myocardial Ischemia Secondary to
Synthetic Cannabinoid (K2) Use in Pediatric Patients. J Pediatr 167, 757-61.e1
(2015).
23. Al Suleimani, Y. M., Al Mahruqi, A. S. & Hiley, C. R. Mechanisms of
vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat
small mesenteric artery. Eur J Pharmacol 765, 107-114 (2015).
24. Sevinc, M. M. et al. Extraordinary cause of acute gastric dilatation and hepatic
portal venous gas: Chronic use of synthetic cannabinoid. World J Gastroenterol 21,
10704-10708 (2015).
25. Maccarrone, M. et al. Endocannabinoid signaling at the periphery: 50 years after
THC. Trends Pharmacol Sci 36, 277-296 (2015).
26. Ali, R. M. et al. Effects of cannabidiol on contractions and calcium signaling in rat
ventricular myocytes. Cell Calcium 57, 290-299 (2015).
27. Atik, S. U. et al. Cardiovascular side effects related with use of synthetic
cannabinoids “bonzai” : two case reports. Turk Pediatri Ars 50, 61-64 (2015).
28. Stanley, C. P., Hind, W. H., Tufarelli, C. & O’Sullivan, S. E. Cannabidiol causes
endothelium-dependent vasorelaxation of human mesenteric arteries via CB1
activation. Cardiovasc Res 107, 568-578 (2015).
29. Karam, K., Abbasi, S. & Khan, F. A. Anaesthetic consideration in a cannabis
addict. J Coll Physicians Surg Pak 25 Suppl 1, S2-3 (2015).
30. Kollins, S. H. et al. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on
cardiovascular function, subjective effects, and performance in healthy adults. J
Subst Abuse Treat 48, 96-103 (2015).
31. Kremshofer, J. et al. A role for GPR55 in human placental venous endothelial cells.
Histochem Cell Biol 144, 49-58 (2015).
32. Li, L. et al. A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-
Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix
Metalloproteinase Expression in Rats. Transl Stroke Res 6, 467-477 (2015).
33. Karabowicz, P., Grzęda, E., Baranowska-Kuczko, M. & Malinowska, B. [Role of
endocannabinoid 2-arachidonoylglycerol in the physiology and pathophysiology of
the cardiovascular system]. Postepy Hig Med Dosw (Online) 68, 814-827 (2014).
34. Stanley, C. & O’Sullivan, S. E. Vascular targets for cannabinoids: animal and
human studies. Br J Pharmacol 171, 1361-1378 (2014).
35. Morty, R. E. & Kuebler, W. M. TRPV4: an exciting new target to promote
alveolocapillary barrier function. Am J Physiol Lung Cell Mol Physiol 307, L817-21
(2014).
36. Li, X. H. et al. The hypotensive effect of intrathecally injected (m)VD-
hemopressin(α) in urethane-anesthetized rats. Peptides 56, 45-51 (2014).
37. O’Keefe, L., Simcocks, A. C., Hryciw, D. H., Mathai, M. L. & McAinch, A. J. The
cannabinoid receptor 1 and its role in influencing peripheral metabolism. Diabetes
Obes Metab 16, 294-304 (2014).
38. Sutamtewagul, G., Sood, V. & Nugent, K. Sympathomimetic syndrome,
choreoathetosis, and acute kidney injury following “bath salts” injection. Clin
Nephrol 81, 63-66 (2014).
39. Bolognesi, M., Di Pascoli, M., Verardo, A. & Gatta, A. Splanchnic vasodilation and
hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 20, 2555-
2563 (2014).
40. Schiavon, A. P. et al. Protective effects of cannabidiol against hippocampal cell
death and cognitive impairment induced by bilateral common carotid artery
occlusion in mice. Neurotox Res 26, 307-316 (2014).
41. Pendergraft, W. F., Herlitz, L. C., Thornley-Brown, D., Rosner, M. & Niles, J. L.
Nephrotoxic effects of common and emerging drugs of abuse. Clin J Am Soc
Nephrol 9, 1996-2005 (2014).
42. Benbadis, S. R. et al. Medical marijuana in neurology. Expert Rev Neurother 14,
1453-1465 (2014).
43. Lu, Y., Akinwumi, B. C., Shao, Z. & Anderson, H. D. Ligand activation of
cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes. J
Cardiovasc Pharmacol 64, 420-430 (2014).
44. Wolff, V. et al. High frequency of intracranial arterial stenosis and cannabis use in
ischaemic stroke in the young. Cerebrovasc Dis 37, 438-443 (2014).
45. Vendel, E. & de Lange, E. C. Functions of the CB1 and CB 2 receptors in
neuroprotection at the level of the blood-brain barrier. Neuromolecular Med 16,
620-642 (2014).
46. Al Kury, L. T. et al. Effects of the endogenous cannabinoid anandamide on voltage-
dependent sodium and calcium channels in rat ventricular myocytes. Br J
Pharmacol 171, 3485-3498 (2014).
47. Wang, Y. et al. Effects of cannabinoid receptor type 2 on endogenous myocardial
regeneration by activating cardiac progenitor cells in mouse infarcted heart. Sci
China Life Sci 57, 201-208 (2014).
48. Gugelmann, H. et al. Crazy Monkey’ poisons man and dog: Human and canine
seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila) 52, 635-
638 (2014).
49. Bialuk, I., Dobosz, K., Potrzebowski, B. & Winnicka, M. M. CP55,940 attenuates
spatial memory retrieval in mice. Pharmacol Rep 66, 931-936 (2014).
50. Calik, M. W. & Carley, D. W. Cannabinoid type 1 and type 2 receptor antagonists
prevent attenuation of serotonin-induced reflex apneas by dronabinol in Sprague-
Dawley rats. PLoS One 9, e111412 (2014).
51. Purohit, V., Rapaka, R. S. & Rutter, J. Cannabinoid receptor-2 and HIV-associated
neurocognitive disorders. J Neuroimmune Pharmacol 9, 447-453 (2014).
52. Sánchez-Pastor, E. et al. Cannabinoid receptor type 1 activation by
arachidonylcyclopropylamide in rat aortic rings causes vasorelaxation involving
calcium-activated potassium channel subunit alpha-1 and calcium channel, voltage-
dependent, L type, alpha 1C subunit. Eur J Pharmacol 729, 100-106 (2014).
53. Raborn, E. S., Jamerson, M., Marciano-Cabral, F. & Cabral, G. A. Cannabinoid
inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to
extracellular matrix proteins. Life Sci 104, 15-23 (2014).
54. MacIntyre, J. et al. Cannabinoid and lipid-mediated vasorelaxation in retinal
microvasculature. Eur J Pharmacol 735, 105-114 (2014).
55. Wheal, A. J., Cipriano, M., Fowler, C. J., Randall, M. D. & O’Sullivan, S. E.
Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through
cyclooxygenase activation. J Pharmacol Exp Ther 351, 457-466 (2014).
56. Zubrzycki, M., Liebold, A., Janecka, A. & Zubrzycka, M. A new face of
endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol 65, 171-181 (2014).
57. Sawicka, J. et al. [Acute novel drugs poisoning among patients of Nofer Institute of Occupational Medicine in Lodz, Toxicology Unit, hospitalized in the years 2008- 2012–epidemiology, clinical state]. Przegl Lek 70, 520-524 (2013).
58. Wiegand, T., Wax, P., Smith, E., Hart, K. & Brent, J. The Toxicology Investigators Consortium Case Registry–the 2012 experience. J Med Toxicol 9, 380-404 (2013).
59. Zogopoulos, P., Vasileiou, I., Patsouris, E. & Theocharis, S. E. The role of endocannabinoids in pain modulation. Fundam Clin Pharmacol 27, 64-80 (2013).
60. Baldassarre, M. et al. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int 33, 1298-1308 (2013).
61. Kola, B. et al. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J 27, 5112-5121 (2013).
62. Wong, G. T. & Irwin, M. G. Poisoning with illicit substances: toxicology for the anaesthetist. Anaesthesia 68 Suppl 1, 117-124 (2013).
63. Pacher, P. & Kunos, G. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J 280, 1918-1943 (2013).
64. Stanley, C. P., Hind, W. H. & O’Sullivan, S. E. Is the cardiovascular system a therapeutic target for cannabidiol. Br J Clin Pharmacol 75, 313-322 (2013).
65. Bełtowski, J. Endogenous hydrogen sulfide in perivascular adipose tissue: role in the regulation of vascular tone in physiology and pathology. Can J Physiol Pharmacol 91, 889-898 (2013).
66. Scerif, M. et al. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. J Endocrinol 219, 79-88 (2013).
67. Fouad, A. A., Albuali, W. H., Al-Mulhim, A. S. & Jresat, I. Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol 36, 347-357 (2013).
68. Stanley, C. P., Wheal, A. J., Randall, M. D. & O’Sullivan, S. E. Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. Eur J Pharmacol 720, 376-382 (2013).
69. Li, Q., Cui, N., Du, Y., Ma, H. & Zhang, Y. Anandamide reduces intracellular Ca2+ concentration through suppression of Na+/Ca2+ exchanger current in rat cardiac myocytes. PLoS One 8, e63386 (2013).
70. Li, Q., Wang, F., Zhang, Y. M., Zhou, J. J. & Zhang, Y. Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis. Cell Physiol Biochem 31, 693-702 (2013).
71. Kargl, J. et al. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 346, 54- 66 (2013).
72. Maslov, L. N. et al. [Role of receptor transactivation in the cardioprotective effects of preconditioning and postconditioning]. Ross Fiziol Zh Im I M Sechenova 98, 305-317 (2012).
73. Maslov, L. N., Lasukova, O. V., Krylatov, A. V., Khanush, L. & Lishmanov, I. [Mediated role of NO-syntase, protein kinase C and KATP-channels in realization of cardioprotective impact of cannabinoid HU-210]. Eksp Klin Farmakol 75, 15-18 (2012).
74. Caramia, G. [Essential fatty acids and lipid mediators. Endocannabinoids]. Pediatr Med Chir 34, 65-72 (2012).
75. Capettini, L. S. et al. Update on the role of cannabinoid receptors after ischemic stroke. Mediators Inflamm 2012, 824093 (2012).
76. Malinowska, B., Baranowska-Kuczko, M. & Schlicker, E. Triphasic blood pressure responses to cannabinoids: do we understand the mechanism. Br J Pharmacol 165, 2073-2088 (2012).
77. Horváth, B., Mukhopadhyay, P., Haskó, G. & Pacher, P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 180, 432-442 (2012).
78. Montecucco, F. et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 33, 846-856 (2012).
79. Pertwee, R. G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367, 3353-3363 (2012).
80. Bol, M., Leybaert, L. & Vanheel, B. Influence of methanandamide and CGRP on potassium currents in smooth muscle cells of small mesenteric arteries. Pflugers Arch 463, 669-677 (2012).
81. Cumella, J. et al. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem 7, 452-463 (2012).
82. Vasic, N., Connemann, B. J., Wolf, R. C., Tumani, H. & Brettschneider, J. Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand. Eur Arch Psychiatry Clin Neurosci 262, 375-391 (2012).
83. Singla, S., Sachdeva, R. & Mehta, J. L. Cannabinoids and atherosclerotic coronary heart disease. Clin Cardiol 35, 329-335 (2012).
84. Wang, P. F. et al. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. J Cardiovasc Pharmacol 59, 301-307 (2012).
85. Montecucco, F. & Di Marzo, V. At the heart of the matter: the endocannabinoid
system in cardiovascular function and dysfunction. Trends Pharmacol Sci 33, 331-
340 (2012).
86. Roy, A. et al. Anandamide modulates carotid sinus nerve afferent activity via
TRPV1 receptors increasing responses to heat. J Appl Physiol (1985) 112, 212-224
(2012).
87. Tamaki, C. et al. Anandamide induces endothelium-dependent vasoconstriction and
CGRPergic nerve-mediated vasodilatation in the rat mesenteric vascular bed. J
Pharmacol Sci 118, 496-505 (2012).
88. Ramirez, S. H. et al. Activation of cannabinoid receptor 2 attenuates leukocyte-
endothelial cell interactions and blood-brain barrier dysfunction under
inflammatory conditions. J Neurosci 32, 4004-4016 (2012).
89. Leblanc, A. et al. [Cannabis and myocardial infarction without angiographic
stenosis in young patient: guilty or not guilty? A case report]. Ann Cardiol Angeiol
(Paris) 60, 154-158 (2011).
90. Rahn, E. J. et al. Pharmacological characterization of AM1710, a putative
cannabinoid CB2 agonist from the cannabilactone class: antinociception without
central nervous system side-effects. Pharmacol Biochem Behav 98, 493-502 (2011).
91. Thapa, D. et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents
inhibit cell proliferation and tumor angiogenesis. Eur J Pharmacol 650, 64-71
(2011).
92. Rossi, B. et al. Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of
encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent
mechanism. J Neuroimmunol 233, 97-105 (2011).
93. Cunha, P., Romão, A. M., Mascarenhas-Melo, F., Teixeira, H. M. & Reis, F.
Endocannabinoid system in cardiovascular disorders – new pharmacotherapeutic
opportunities. J Pharm Bioallied Sci 3, 350-360 (2011).
94. Wolff, V. et al. Cannabis use, ischemic stroke, and multifocal intracranial
vasoconstriction: a prospective study in 48 consecutive young patients. Stroke 42,
1778-1780 (2011).
95. González, C. et al. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–
reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and
iNOS/eNOS. Diabetes Metab Res Rev 27, 331-340 (2011).
96. Abalo, R. et al. Cannabinoid-induced delayed gastric emptying is selectively
increased upon intermittent administration in the rat: role of CB1 receptors.
Neurogastroenterol Motil 23, 457-67, e177 (2011).
97. Zhang, H., Hilton, D. A., Hanemann, C. O. & Zajicek, J. Cannabinoid receptor and
N-acyl phosphatidylethanolamine phospholipase D–evidence for altered expression
in multiple sclerosis. Brain Pathol 21, 544-557 (2011).
98. Ruiz-Valdepeñas, L. et al. Cannabidiol reduces lipopolysaccharide-induced
vascular changes and inflammation in the mouse brain: an intravital microscopy
study. J Neuroinflammation 8, 5 (2011).
99. Booz, G. W. Cannabidiol as an emergent therapeutic strategy for lessening the
impact of inflammation on oxidative stress. Free Radic Biol Med 51, 1054-1061
(2011).
100. Mestre, L. et al. Anandamide inhibits Theiler’s virus induced VCAM-1 in brain
endothelial cells and reduces leukocyte transmigration in a model of blood brain
barrier by activation of CB(1) receptors. J Neuroinflammation 8, 102 (2011).
101. Reichenbach, V., Ros, J. & Jiménez, W. [Endogenous cannabinoids in liver disease:
Many darts for a single target]. Gastroenterol Hepatol 33, 323-329 (2010).
102. Zhao, Y. et al. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur J Pharmacol 649, 285- 292 (2010).
103. Brunet, B. et al. Postmortem redistribution of THC in the pig. Int J Legal Med 124, 543-549 (2010).
104. Zuurman, L. et al. Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers. J Psychopharmacol 24, 1689-1696 (2010).
105. Mair, K. M. et al. Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br J Pharmacol 161, 176-192 (2010).
106. Taylor, A. H., Abbas, M. S., Habiba, M. A. & Konje, J. C. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol 133, 557-565 (2010).
107. Amorós, I. et al. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. J Mol Cell Cardiol 48, 201-210 (2010).
108. Barana, A. et al. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc Res 85, 56-67 (2010).
109. Nagarkatti, M., Rieder, S. A., Hegde, V. L., Kanada, S. & Nagarkatti, P. Do cannabinoids have a therapeutic role in transplantation. Trends Pharmacol Sci 31, 345-350 (2010).
110. Albion, C., Shkrum, M. & Cairns, J. Contributing factors to methadone-related deaths in Ontario. Am J Forensic Med Pathol 31, 313-319 (2010).
111. Mingorance, C., de Sotomayor, M. A., Marhuenda, E. & Herrera, M. D. Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo- oxygenase-derived products on arteries from obese Zucker rats. J Cardiovasc Pharmacol 56, 560-569 (2010).
112. Rajesh, M. et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol 160, 688-700 (2010).
113. Patel, K. D., Davison, J. S., Pittman, Q. J. & Sharkey, K. A. Cannabinoid CB(2) receptors in health and disease. Curr Med Chem 17, 1393-1410 (2010).
114. Alves, F. H. et al. Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res 62, 228- 236 (2010).
115. Rajesh, M. et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56, 2115-2125 (2010).
116. Hu, S. S. et al. Architecture of cannabinoid signaling in mouse retina. J Comp Neurol 518, 3848-3866 (2010).
117. Zhao, Y. et al. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 55,
292-298 (2010).
118. Zakrzeska, A. et al. A cannabinoid receptor, sensitive to O-1918, is involved in the
delayed hypotension induced by anandamide in anaesthetized rats. Br J Pharmacol
160, 574-584 (2010).
119. O’Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D. & Kendall, D. A. Time-
dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612,
61-68 (2009).
120. Caraceni, P., Domenicali, M., Giannone, F. & Bernardi, M. The role of the
endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab
23, 65-77 (2009).
121. Rutkowska, M. & Gliniak, H. The influence of ACEA–a selective cannabinoid
CB1 receptor agonist on whole blood and platelet-poor plasma serotonin
concentrations. Pharmazie 64, 598-601 (2009).
122. Kennedy, S., Kane, K. A., Pyne, N. J. & Pyne, S. Targeting sphingosine-1-
phosphate signalling for cardioprotection. Curr Opin Pharmacol 9, 194-201 (2009).
123. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB2 receptors
and the endocannabinoid system for the treatment of pain. Brain Res Rev 60, 255-
266 (2009).
124. Schley, M. et al. Predominant CB2 receptor expression in endothelial cells of
glioblastoma in humans. Brain Res Bull 79, 333-337 (2009).
125. Galal, A. M. et al. Naturally occurring and related synthetic cannabinoids and their
potential therapeutic applications. Recent Pat CNS Drug Discov 4, 112-136 (2009).
126. Dauchy, S. et al. Expression and transcriptional regulation of ABC transporters and
cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells.
Biochem Pharmacol 77, 897-909 (2009).
127. Hiley, C. R. Endocannabinoids and the heart. J Cardiovasc Pharmacol 53, 267-276
(2009).
128. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor agonists as
medicines. Br J Pharmacol 156, 397-411 (2009).
129. Mingorance, C. et al. Effects of chronic treatment with the CB1 antagonist,
rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats.
Obesity (Silver Spring) 17, 1340-1347 (2009).
130. Montecucco, F. et al. CB(2) cannabinoid receptor activation is cardioprotective in a
mouse model of ischemia/reperfusion. J Mol Cell Cardiol 46, 612-620 (2009).
131. Butler, H. & Korbonits, M. Cannabinoids for clinicians: the rise and fall of the
cannabinoid antagonists. Eur J Endocrinol 161, 655-662 (2009).
132. Hall, W. & Degenhardt, L. Adverse health effects of non-medical cannabis use.
Lancet 374, 1383-1391 (2009).
133. Resstel, L. B. et al. 5-HT1A receptors are involved in the cannabidiol-induced
attenuation of behavioural and cardiovascular responses to acute restraint stress in
rats. Br J Pharmacol 156, 181-188 (2009).
134. Pagotto, U., Vanuzzo, D., Vicennati, V. & Pasquali, R. [Pharmacological therapy of
obesity]. G Ital Cardiol (Rome) 9, 83S-93S (2008).
135. Rudź, R., Baranowska, U. & Malinowska, B. [Function of cannabinoids in heart
failure]. Postepy Hig Med Dosw (Online) 62, 174-184 (2008).
136. Kozłowska, H. et al. Virodhamine relaxes the human pulmonary artery through the
endothelial cannabinoid receptor and indirectly through a COX product. Br J
Pharmacol 155, 1034-1042 (2008).
137. Lípez-Miranda, V., Herradón, E. & Martín, M. I. Vasorelaxation caused by
cannabinoids: mechanisms in different vascular beds. Curr Vasc Pharmacol 6, 335-
346 (2008).
138. Oltmanns, M. H. et al. Topical WIN55212-2 alleviates intraocular hypertension in
rats through a CB1 receptor mediated mechanism of action. J Ocul Pharmacol Ther
24, 104-115 (2008).
139. Mach, F. & Steffens, S. The role of the endocannabinoid system in atherosclerosis.
J Neuroendocrinol 20 Suppl 1, 53-57 (2008).
140. Caraceni, P., Domenicali, M. & Bernardi, M. The endocannabinoid system and
liver diseases. J Neuroendocrinol 20 Suppl 1, 47-52 (2008).
141. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce. Nat Rev
Drug Discov 7, 438-455 (2008).
142. van Diepen, H., Schlicker, E. & Michel, M. C. Prejunctional and peripheral effects
of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).
Naunyn Schmiedebergs Arch Pharmacol 378, 345-369 (2008).
143. Pacher, P. et al. Modulation of the endocannabinoid system in cardiovascular
disease: therapeutic potential and limitations. Hypertension 52, 601-607 (2008).
144. Currie, S. et al. IP(3)R-mediated Ca(2+) release is modulated by anandamide in
isolated cardiac nuclei. J Mol Cell Cardiol 45, 804-811 (2008).
145. Hajrasouliha, A. R. et al. Endogenous cannabinoids contribute to remote ischemic
preconditioning via cannabinoid CB2 receptors in the rat heart. Eur J Pharmacol
579, 246-252 (2008).
146. Sarzani, R. Endocannabinoids, blood pressure and the human heart. J
Neuroendocrinol 20 Suppl 1, 58-62 (2008).
147. Moezi, L., Gaskari, S. A. & Lee, S. S. Endocannabinoids and liver disease. V.
endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.
Am J Physiol Gastrointest Liver Physiol 295, G649-53 (2008).
148. Bonhomme-Faivre, L., Benyamina, A., Reynaud, M., Farinotti, R. & Abbara, C.
Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-
glycoprotein. Addict Biol 13, 295-300 (2008).
149. Durmaz, R. et al. Dexanabinol prevents development of vasospasm in the rat
femoral artery model. Neurosurg Rev 31, 215-23; discussion 223 (2008).
150. Rajesh, M. et al. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced
human vascular smooth muscle cell proliferation and migration. Br J Pharmacol
153, 347-357 (2008).
151. Lu, T. S. et al. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain
microvascular endothelial cells. J Immunol 181, 6406-6416 (2008).
152. Rajesh, M., Mukhopadhyay, P., Haskó, G. & Pacher, P. Cannabinoid CB1 receptor
inhibition decreases vascular smooth muscle migration and proliferation. Biochem
Biophys Res Commun 377, 1248-1252 (2008).
153. Grassi, G. et al. Blood pressure lowering effects of rimonabant in obesity-related
hypertension. J Neuroendocrinol 20 Suppl 1, 63-68 (2008).
154. Krylatov, A. V. et al. [Significance of cardiac cannabinoid receptors in regulation of
cardiac rhythm, myocardial contractility, and electrophysiologic processes in heart].
Izv Akad Nauk Ser Biol 35-44 (2007).
155. Bramlage, P. et al. [Prevention of cardiovascular disease by blocking the
endocannabinoid system]. Herz 32, 560-567 (2007).
156. Scheen, A. J. & Van Gaal, L. F. [Cardiometabolic effects of rimonabant in
obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Rev Med Liege
62, 81-85 (2007).
157. Hoi, P. M. et al. Vascular pharmacology of a novel cannabinoid-like compound, 3-
(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide
(VSN16) in the rat. Br J Pharmacol 152, 751-764 (2007).
158. Johns, D. G. et al. The novel endocannabinoid receptor GPR55 is activated by
atypical cannabinoids but does not mediate their vasodilator effects. Br J
Pharmacol 152, 825-831 (2007).
159. Després, J. P. The endocannabinoid system: a new target for the regulation of
energy balance and metabolism. Crit Pathw Cardiol 6, 46-50 (2007).
160. Yang, Y. Y. et al. Role of Ca2+-dependent potassium channels in in vitro
anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. Liver
Int 27, 1045-1055 (2007).
161. Rog, D. J., Nurmikko, T. J. & Young, C. A. Oromucosal delta9-
tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29, 2068- 2079 (2007).
162. Stern, N., Osher, E. & Greenman, Y. Hypoadiponectinemia as a marker of adipocyte dysfunction — Part I: the biology of adiponectin. J Cardiometab Syndr 2, 174-182 (2007).
163. Hiley, C. R. & Kaup, S. S. GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 152, 559-561 (2007).
164. Lépicier, P., Lagneux, C., Sirois, M. G. & Lamontagne, D. Endothelial CB1- receptors limit infarct size through NO formation in rat isolated hearts. Life Sci 81, 1373-1380 (2007).
165. Randall, M. D. Endocannabinoids and the haematological system. Br J Pharmacol 152, 671-675 (2007).
166. Wheal, A. J., Bennett, T., Randall, M. D. & Gardiner, S. M. Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro. Br J Pharmacol 150, 662-671 (2007).
167. Plange, N. et al. Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 143, 173-174 (2007).
168. Zani, A., Braida, D., Capurro, V. & Sala, M. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol 152, 1301-1311 (2007).
169. Wilkinson, J. D., Kendall, D. A. & Ralevic, V. Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed. Br J Pharmacol 152, 709-716 (2007).
170. Rajesh, M. et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-
endothelial adhesion. Am J Physiol Heart Circ Physiol 293, H2210-8 (2007).
171. Wheal, A. J., Bennett, T., Randall, M. D. & Gardiner, S. M. Cardiovascular effects
of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 152,
717-724 (2007).
172. Pakdeechote, P., Dunn, W. R. & Ralevic, V. Cannabinoids inhibit noradrenergic
and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial
bed. Br J Pharmacol 152, 725-733 (2007).
173. Mendizábal, V. E. & Adler-Graschinsky, E. Cannabinoids as therapeutic agents in
cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 151, 427-
440 (2007).
174. Ashton, J. C. & Smith, P. F. Cannabinoids and cardiovascular disease: the outlook
for clinical treatments. Curr Vasc Pharmacol 5, 175-185 (2007).
175. Zhang, X., Wang, J. F., Kunos, G. & Groopman, J. E. Cannabinoid modulation of
Kaposi’s sarcoma-associated herpesvirus infection and transformation. Cancer Res
67, 7230-7237 (2007).
176. Durst, R. et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects
against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol
293, H3602-7 (2007).
177. Kogan, N. M. et al. A cannabinoid anticancer quinone, HU-331, is more potent and
less cardiotoxic than doxorubicin: a comparative in vivo study. J Pharmacol Exp
Ther 322, 646-653 (2007).
178. Su, J. Y. & Vo, A. C. 2-Arachidonylglyceryl ether and abnormal cannabidiol-
induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol 559, 189-195 (2007).
179. Lamontagne, D., Lépicier, P., Lagneux, C. & Bouchard, J. F. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Arch Mal Coeur Vaiss 99, 242-246 (2006).
180. Francischetti, E. A. & de Abreu, V. G. The endocannabinoid system: a new perspective for cardiometabolic risk control. Arq Bras Cardiol 87, 548-558 (2006).
181. Arora, S. & Anubhuti. Role of neuropeptides in appetite regulation and obesity–a review. Neuropeptides 40, 375-401 (2006).
182. El-Remessy, A. B. et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168, 235-244 (2006).
183. Krylatov, A. V. et al. Negative chronotropic effect of cannabinoids and their water- soluble emulsion is related to activation of cardiac CB1 receptors. Bull Exp Biol Med 142, 450-453 (2006).
184. Breyne, J. & Vanheel, B. Methanandamide hyperpolarizes gastric arteries by stimulation of TRPV1 receptors on perivascular CGRP containing nerves. J Cardiovasc Pharmacol 47, 303-309 (2006).
185. O’Sullivan, S. E., Kendall, D. A. & Randall, M. D. Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 317, 428-438 (2006).
186. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 283, 75-83 (2006).
187. Breyne, J., Van de Voorde, J. & Vanheel, B. Characterization of the vasorelaxation to methanandamide in rat gastric arteries. Can J Physiol Pharmacol 84, 1121-1132 (2006).
188. Mackie, K. & Stella, N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8, E298-306 (2006).
189. Ghosh, S., Preet, A., Groopman, J. E. & Ganju, R. K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43, 2169-2179 (2006).
190. Duflou, J., Nickols, G., Waite, P., Griffiths, R. & Sage, M. Artefactual contraction band necrosis of the myocardium in fatal air crashes. Aviat Space Environ Med 77, 944-949 (2006).
191. Sade, H., Muraki, K., Ohya, S., Hatano, N. & Imaizumi, Y. Activation of large- conductance, Ca2+-activated K+ channels by cannabinoids. Am J Physiol Cell Physiol 290, C77-86 (2006).
192. Kogan, N. M. et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 70, 51-59 (2006).
193. Kunsdorf-Wnuk, A., Musioł, E., Karpel, E. & Arct-Danielak, D. [Rhabdomyolysis, disseminated intravascular coagulation and acute renal failure after severe narcotics intoxication (MDMA, THC, amphetamine)]. Pol Merkur Lekarski 18, 436-439 (2005).
194. Kwolek, G., Zakrzeska, A., Kozłowska, H. & Malinowska, B. [Influence of anandamide, the endogenous agonist of cannabinoid receptors on the circulatory system]. Postepy Hig Med Dosw (Online) 59, 208-218 (2005).
195. Ribuot, C., Lamontagne, D. & Godin-Ribuot, D. [Cardiac and vascular effects of cannabinoids: toward a therapeutic use?]. Ann Cardiol Angeiol (Paris) 54, 89-96 (2005).
196. Wang, Y., Kaminski, N. E. & Wang, D. H. VR1-mediated depressor effects during high-salt intake: role of anandamide. Hypertension 46, 986-991 (2005).
197. O’Sullivan, S. E., Kendall, D. A. & Randall, M. D. Vascular effects of delta 9- tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur J Pharmacol 507, 211-221 (2005).
198. Wahn, H., Wolf, J., Kram, F., Frantz, S. & Wagner, J. A. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 289, H2491-6 (2005).
199. O’Sullivan, S. E., Kendall, D. A. & Randall, M. D. The effects of Delta9- tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145, 514-526 (2005).
200. O’Sullivan, S. E., Tarling, E. J., Bennett, A. J., Kendall, D. A. & Randall, M. D. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337, 824-831 (2005).
201. Gardiner, S. M., March, J. E., Kemp, P. A. & Bennett, T. Involvement of CB1- receptors and beta-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats. Am J Physiol Heart Circ Physiol 288, H2280-8 (2005).
202. Pacher, P. et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 289, H533-41 (2005).
203. Cho, C. M., Hirsch, R. & Johnstone, S. General and oral health implications of cannabis use. Aust Dent J 50, 70-74 (2005).
204. Movahed, P. et al. Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 280, 38496-38504 (2005).
205. Sheridan, R. D., Turner, S. R., Cooper, G. J. & Tattersall, J. E. Effects of seven drugs of abuse on action potential repolarisation in sheep cardiac Purkinje fibres. Eur J Pharmacol 511, 99-107 (2005).
206. Croxford, J. L., Wang, K., Miller, S. D., Engman, D. M. & Tyler, K. M. Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. Cell Microbiol 7, 1592-1602 (2005).
207. Libiseller, K., Pavlic, M., Grubwieser, P. & Rabl, W. Ecstasy–deadly risk even outside rave parties. Forensic Sci Int 153, 227-230 (2005).
208. Sterin-Borda, L., Del Zar, C. F. & Borda, E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol 69, 1705-1713 (2005).
209. Wagner, J. A., Abesser, M., Karcher, J., Laser, M. & Kunos, G. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol 46, 348-355 (2005).
210. Pacher, P., Bátkai, S. & Kunos, G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 599-625 (2005).
211. Kola, B. et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280, 25196- 25201 (2005).
212. Krylatov, A. V., Maslov, L. N., Lasukova, O. V. & Pertwee, R. G. Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart. Bull Exp Biol Med 139, 558-561 (2005).
213. Schultheiss, T., Flau, K., Kathmann, M., Göthert, M. & Schlicker, E. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta. Naunyn Schmiedebergs Arch Pharmacol 372, 139- 146 (2005).
214. Pacher, P., Bátkai, S. & Kunos, G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48, 1130-1138 (2005).
215. Valverde, O., Karsak, M. & Zimmer, A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 117-145 (2005).
216. Flesch, M. & Erdmann, E. [Racing heart and angina pectoris in a 19-year-old male. Possibly the result of cannabis smoking?]. MMW Fortschr Med 146, 16 (2004).
217. Ho, W. S. & Hiley, C. R. Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 56, 869- 875 (2004).
218. Randall, M. D., Kendall, D. A. & O’Sullivan, S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142, 20-26 (2004).
219. Maslov, L. N., Lasukova, O. V., Krylatov, A. V., Uzhachenko, R. V. & Pertwee, R. Selective cannabinoid receptor agonist HU-210 decreases pump function of isolated perfused heart: role of cAMP and cGMP. Bull Exp Biol Med 138, 550-553 (2004).
220. Grotenhermen, F. Pharmacology of cannabinoids. Neuro Endocrinol Lett 25, 14-23 (2004).
221. Ashton, J. C., Appleton, I., Darlington, C. L. & Smith, P. F. Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J Cardiovasc Pharmacol 44, 517-519 (2004).
222. Battista, N., Fezza, F. & Maccarrone, M. Endocannabinoids and their involvement in the neurovascular system. Curr Neurovasc Res 1, 129-140 (2004).
223. Bátkai, S. et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996-2002 (2004).
224. Ponto, L. L. et al. Effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O]water: effect in occasional and chronic users. J Clin Pharmacol 44, 751-766 (2004).
225. Duncan, M., Kendall, D. A. & Ralevic, V. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. J Pharmacol Exp Ther 311, 411-419 (2004).
226. Hiley, C. R. & Ford, W. R. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 79, 187-205 (2004).
227. Bátkai, S., Pacher, P., Járai, Z., Wagner, J. A. & Kunos, G. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 287, H595-600 (2004).
228. Mo, F. M., Offertáler, L. & Kunos, G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489, 21-27 (2004).
229. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28, 849-863 (2004).
230. Maslov, L. N., Lasukova, O. V., Krylatov, A. V., Lishmanov, I. & Pertwee, R. [Alterations of inotropic function of isolated heart and extent of injury of cardiomyocytes after cannabinoid receptor activation during ischemia and reperfusion]. Ross Fiziol Zh Im I M Sechenova 89, 1108-1116 (2003).
231. Radbruch, L. & Nauck, F. [A review of side effects and complications with cannabinoid treatment]. Schmerz 17, 274-279 (2003).
232. Ho, W. S. & Hiley, C. R. Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138, 1320-1332 (2003).
233. Niederhoffer, N., Schmid, K. & Szabo, B. The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 367, 434-443 (2003).
234. Offertáler, L. et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63, 699-705 (2003).
235. Mathew, R. J., Wilson, W. H. & Davis, R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav 75, 309-318 (2003).
236. Blázquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17,
529-531 (2003).
237. Begg, M. et al. G protein-coupled endothelial receptor for atypical cannabinoid
ligands modulates a Ca2+-dependent K+ current. J Biol Chem 278, 46188-46194
(2003).
238. Ho, W. S. & Hiley, C. R. Endothelium-independent relaxation to cannabinoids in
rat-isolated mesenteric artery and role of Ca2+ influx. Br J Pharmacol 139, 585-
597 (2003).
239. Hiley, C. R. & Ford, W. R. Endocannabinoids as mediators in the heart: a potential
target for therapy of remodelling after myocardial infarction. Br J Pharmacol 138,
1183-1184 (2003).
240. Bouchard, J. F., Lépicier, P. & Lamontagne, D. Contribution of endocannabinoids
in the endothelial protection afforded by ischemic preconditioning in the isolated rat
heart. Life Sci 72, 1859-1870 (2003).
241. Bonz, A. et al. Cannabinoids acting on CB1 receptors decrease contractile
performance in human atrial muscle. J Cardiovasc Pharmacol 41, 657-664 (2003).
242. Mendizábal, V. E. & Adler-Graschinsky, E. Cannabinoid system as a potential
target for drug development in the treatment of cardiovascular disease. Curr Vasc
Pharmacol 1, 301-313 (2003).
243. Godlewski, G., Göthert, M. & Malinowska, B. Cannabinoid receptor-independent
inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von
Bezold-Jarisch reflex. Br J Pharmacol 138, 767-774 (2003).
244. Pozzi, O., Misiano, P., Clark, G. D. & Visentin, L. Antagonism between the anti-
inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
Pharmacology 69, 158-163 (2003).
245. Randall, M. D. A new endothelial target for cannabinoids. Mol Pharmacol 63, 469-
470 (2003).
246. Járai, Z. & Kúnos, G. [Cardiovascular effects of cannabinoids]. Orv Hetil 143,
1563-1568 (2002).
247. Kenny, L. C., Baker, P. N., Kendall, D. A., Randall, M. D. & Dunn, W. R. The role
of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br J Pharmacol 136, 1085-1088 (2002).
248. Kunos, G. et al. The quest for a vascular endothelial cannabinoid receptor. Chem Phys Lipids 121, 45-56 (2002).
249. Brandes, R. P. et al. The extracellular regulated kinases (ERK) 1/2 mediate cannabinoid-induced inhibition of gap junctional communication in endothelial cells. Br J Pharmacol 136, 709-716 (2002).
250. Kozak, K. R. et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 44877-44885 (2002).
251. Gardiner, S. M., March, J. E., Kemp, P. A. & Bennett, T. Influence of the CB(1) receptor antagonist, AM 251, on the regional haemodynamic effects of WIN- 55212-2 or HU 210 in conscious rats. Br J Pharmacol 136, 581-587 (2002).
252. Ford, W. R., Honan, S. A., White, R. & Hiley, C. R. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 135, 1191-1198 (2002).
253. Ros, J. et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122, 85-93 (2002).
254. Krylatov, A. V. et al. Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull Exp Biol Med 133, 122-124 (2002).
255. Joyeux, M. et al. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55, 619-625 (2002).
256. Zygmunt, P. M., Andersson, D. A. & Hogestatt, E. D. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22, 4720-4727 (2002).
257. Jones, R. T. Cardiovascular system effects of marijuana. J Clin Pharmacol 42, 58S- 63S (2002).
258. Högestätt, E. D. & Zygmunt, P. M. Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 66, 343-351 (2002).
259. Randall, M. D., Harris, D., Kendall, D. A. & Ralevic, V. Cardiovascular effects of cannabinoids. Pharmacol Ther 95, 191-202 (2002).
260. Sidney, S. Cardiovascular consequences of marijuana use. J Clin Pharmacol 42, 64S-70S (2002).
261. Pórszász, R. et al. Capsaicin-induced nonneural vasoconstriction in canine mesenteric arteries. Eur J Pharmacol 441, 173-175 (2002).
262. Ralevic, V. & Kendall, D. A. Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 444, 171-181 (2002).
263. Ralevic, V., Kendall, D. A., Randall, M. D. & Smart, D. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 71, 2577-2594 (2002).
264. Cainazzo, M. M. et al. Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat. Eur J Pharmacol 441, 91-97 (2002).
265. Mukhopadhyay, S., Chapnick, B. M. & Howlett, A. C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 282, H2046-54 (2002).
266. Ugdyzhekova, D. S. et al. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull Exp Biol Med 133, 125-126 (2002).
267. Nahas, G., Harvey, D. J., Sutin, K., Turndorf, H. & Cancro, R. A molecular basis of the therapeutic and psychoactive properties of cannabis (delta9- tetrahydrocannabinol). Prog Neuropsychopharmacol Biol Psychiatry 26, 721-730 (2002).
268. Garcia, N., Járai, Z., Mirshahi, F., Kunos, G. & Sanyal, A. J. Systemic and portal hemodynamic effects of anandamide. Am J Physiol Gastrointest Liver Physiol 280, G14-20 (2001).
269. Vanheel, B. & Van de Voorde, J. Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries. J Pharmacol Exp Ther 296, 322-328 (2001).
270. Shah, V. Portal hypertension and the hyperdynamic circulation: nitric oxide in a haze of cannabinoid smoke. Hepatology 34, 1060-1061 (2001).
271. Kunos, G. & Bátkai, S. Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem Res 26, 1015-1021 (2001).
272. Lagneux, C. & Lamontagne, D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 132, 793-796 (2001).
273. Ottani, A. & Giuliani, D. Hu 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 7, 131-145 (2001).
274. Wagner, J. A., Járai, Z., Bátkai, S. & Kunos, G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423, 203-210 (2001).
275. Gupta, B. D., Jani, C. B. & Shah, P. H. Fatal ‘Bhang’ poisoning. Med Sci Law 41, 349-352 (2001).
276. Szabo, B., Nordheim, U. & Niederhoffer, N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297, 819-826 (2001).
277. Ralevic, V. & Kendall, D. A. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 418, 117-125 (2001).
278. Ralevic, V., Kendall, D. A., Jerman, J. C., Middlemiss, D. N. & Smart, D. Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol 424, 211-219 (2001).
279. Grainger, J. & Boachie-Ansah, G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134, 1003-1012 (2001).
280. Krylatov, A. V. et al. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131, 523-525 (2001).
281. Schiffrin, E. L. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 38 Suppl 2, S3-6 (2001).
282. Kurihara, J. et al. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves. Jpn J Pharmacol 87, 93-96 (2001).
283. Nahas, G. [Cannabis-induced arteriopathy]. Presse Med 29, 845 (2000).
284. Zygmunt, P. M., Chuang, H., Movahed, P., Julius, D. & Högestätt, E. D. The
anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J
Pharmacol 396, 39-42 (2000).
285. Lay, L., Angus, J. A. & Wright, C. E. Pharmacological characterisation of
cannabinoid CB(1) receptors in the rat and mouse. Eur J Pharmacol 391, 151-161
(2000).
286. Ugdyzhekova, D. S., Davydova, Y. G., Maimeskulova, L. A. & Mechoulam, R.
Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine. Bull Exp Biol Med 130, 1087-1089 (2000).
287. Salzet, M. Invertebrate molecular neuroimmune processes. Brain Res Brain Res Rev
34, 69-79 (2000).
288. Van den Bossche, I. & Vanheel, B. Influence of cannabinoids on the delayed
rectifier in freshly dissociated smooth muscle cells of the rat aorta. Br J Pharmacol
131, 85-93 (2000).
289. Kunos, G. et al. Endocannabinoids as cardiovascular modulators. Chem Phys Lipids
108, 159-168 (2000).
290. Hillard, C. J. Endocannabinoids and vascular function. J Pharmacol Exp Ther 294,
27-32 (2000).
291. Kunos, G. et al. Cardiovascular effects of endocannabinoids–the plot thickens.
Prostaglandins Other Lipid Mediat 61, 71-84 (2000).
292. Niederhoffer, N. & Szabo, B. Cannabinoids cause central sympathoexcitation and
bradycardia in rabbits. J Pharmacol Exp Ther 294, 707-713 (2000).
293. Maccarrone, M. et al. Anandamide uptake by human endothelial cells and its
regulation by nitric oxide. J Biol Chem 275, 13484-13492 (2000).
294. Schmid, P. C. et al. A sensitive endocannabinoid assay. The simultaneous analysis
of N-acylethanolamines and 2-monoacylglycerols. Chem Phys Lipids 104, 185-191
(2000).
295. Chaytor, A. T., Martin, P. E., Evans, W. H., Randall, M. D. & Griffith, T. M. The
endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520 Pt 2, 539-550 (1999).
296. Wagner, J. A., Varga, K., Járai, Z. & Kunos, G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33, 429-434 (1999).
297. Katayama, K., Ueda, N., Katoh, I. & Yamamoto, S. Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim Biophys Acta 1440, 205-214 (1999).
298. Niederhoffer, N. & Szabo, B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126, 457- 466 (1999).
299. Krowicki, Z. K., Moerschbaecher, J. M., Winsauer, P. J., Digavalli, S. V. & Hornby, P. J. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 371, 187-196 (1999).